{"protocolSection": {"identificationModule": {"nctId": "NCT03260790", "orgStudyIdInfo": {"id": "16-007731"}, "organization": {"fullName": "Mayo Clinic", "class": "OTHER"}, "briefTitle": "Pneumococcal Vaccines in Patients With Asthma", "officialTitle": "Immunogenicity of PPSV-23 After PCV-13 Vaccination in Adult Asthmatic Patients"}, "statusModule": {"statusVerifiedDate": "2021-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-10-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-12-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-12-25", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-07-31", "studyFirstSubmitQcDate": "2017-08-23", "studyFirstPostDateStruct": {"date": "2017-08-24", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-10-07", "resultsFirstSubmitQcDate": "2021-10-07", "resultsFirstPostDateStruct": {"date": "2021-11-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-10-07", "lastUpdatePostDateStruct": {"date": "2021-11-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Avni Joshi", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Mayo Clinic"}, "leadSponsor": {"name": "Mayo Clinic", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.", "detailedDescription": "Patients will be randomized into either PCV13 and PPSV23 (Experimental) or PPSV23 alone (Active comparator). At the Week 0 time point, the patients will receive either PCV13 (Experimental) or PPSV23 (Active comparator) and undergo a blood draw of 5ml for assessment of pre-vacation serotype titers. The Active Comparator group will undergo a 5ml draw of blood for assessment of titers at week 8, 16, and 24 following vaccination. The Experimental group will undergo vaccination with PPSV23 at week 8 with 5 ml blood draw for pneumococcal serotype titers as well as a blood draw at week 16 and week 24."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Vaccine", "Pneumococcal", "Pneumonia"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 17, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "PCV13 and PPSV23", "type": "EXPERIMENTAL", "description": "Participants randomized to receive PPSV23 primed with PCV13. Participants will receive PCV13 8 weeks prior to receiving PPSV23", "interventionNames": ["Biological: PCV13", "Biological: PPSV23"]}, {"label": "PPSV23", "type": "ACTIVE_COMPARATOR", "description": "Participants randomized to receive PPSV23 alone", "interventionNames": ["Biological: PPSV23"]}], "interventions": [{"type": "BIOLOGICAL", "name": "PCV13", "description": "Single 0.5 ml dose of PCV13 administered via intramuscular injection", "armGroupLabels": ["PCV13 and PPSV23"], "otherNames": ["Prevnar"]}, {"type": "BIOLOGICAL", "name": "PPSV23", "description": "Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously", "armGroupLabels": ["PCV13 and PPSV23", "PPSV23"], "otherNames": ["Pneumovax"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16", "description": "5 ml blood draw for assessment of pneumococcal specific titer IgG. Measured as mcg/dL.", "timeFrame": "Baseline, week 0, week 8, week 16"}, {"measure": "Sum of Anti-pneumococcal IgG to All Serotypes at Baseline, Week 0, Week 8 and Week 16", "description": "5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. Measured as mcg/mL.", "timeFrame": "Baseline, week 0, week 8, week 16"}, {"measure": "Sum of Anti-pneumococcal IgG to Serotypes Common to PCV13 and PPSV23 at Baseline, Week 0, Week 8, Week 16", "description": "5 ml blood draw for assessment of IgG specific Antibody titers for serotypes common PCV13 \\& PPSV23. Measured as mcg/mL.", "timeFrame": "Baseline, week 0, week 8, week 16"}, {"measure": "Sum of Anti-pneumococcal IgG to Serotypes Unique to PPSV23 at Baseline, Week 0, Week 8 and Week 16.", "description": "5 ml blood draw for assessment of IgG specific Antibody titers for serotypes unique to PPSV23. Measured as mcg/mL.", "timeFrame": "Baseline, week 0, week 8, week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n- Diagnosis of asthma\n\nExclusion Criteria:\n\n* Research exemption requested\n* History of PCV-13 vaccination\n* History of cochlear implant\n* Cerebrospinal Fluid (CSF) leak\n* Congestive Heart Failure (CHF)\n* Diabetes Mellitus (DM)\n* Chronic Kidney Disease (CKD)\n* Human Immunodeficiency Virus (HIV)\n* Common Variable Immune Deficiency (CVID)\n* Patients who have received the PPSV23 vaccine in the last 5 years\n* Women who are pregnant will also be excluded from the study by performing 2 point of care urine pregnancy tests ( prior to vaccinations)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "19 Years", "maximumAge": "64 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Avni Y Joshi", "affiliation": "Mayo Clinic", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Mayo Clinic in Rochester", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Mayo Clinic Clinical Trials", "url": "https://www.mayo.edu/research/clinical-trials"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "PCV13 and PPSV23", "description": "Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23\n\nPCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously"}, {"id": "FG001", "title": "PPSV23", "description": "Participants received PPSV23 alone\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "PCV13 and PPSV23", "description": "Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23\n\nPCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously"}, {"id": "BG001", "title": "PPSV23", "description": "Participants received PPSV23 alone\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "17"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "16"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "15"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "16"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "17"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16", "description": "5 ml blood draw for assessment of pneumococcal specific titer IgG. Measured as mcg/dL.", "populationDescription": "Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mcg/dL", "timeFrame": "Baseline, week 0, week 8, week 16", "groups": [{"id": "OG000", "title": "PCV13 and PPSV23", "description": "Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23\n\nPCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously"}, {"id": "OG001", "title": "PPSV23", "description": "Participants received PPSV23 alone\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "109.8", "lowerLimit": "74.3", "upperLimit": "141.8"}, {"groupId": "OG001", "value": "53.9", "lowerLimit": "34.8", "upperLimit": "185.3"}]}]}, {"title": "week 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "142.3", "lowerLimit": "111.7", "upperLimit": "194.6"}, {"groupId": "OG001", "value": "53.9", "lowerLimit": "34.8", "upperLimit": "185.3"}]}]}, {"title": "week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "211.7", "lowerLimit": "184.6", "upperLimit": "271.0"}, {"groupId": "OG001", "value": "243.3", "lowerLimit": "173.4", "upperLimit": "271.0"}]}]}, {"title": "week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "212.0", "lowerLimit": "171.1", "upperLimit": "257.7"}, {"groupId": "OG001", "value": "224.8", "lowerLimit": "196.6", "upperLimit": "271.0"}]}]}]}, {"type": "PRIMARY", "title": "Sum of Anti-pneumococcal IgG to All Serotypes at Baseline, Week 0, Week 8 and Week 16", "description": "5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. Measured as mcg/mL.", "populationDescription": "Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mcg/mL.", "timeFrame": "Baseline, week 0, week 8, week 16", "groups": [{"id": "OG000", "title": "PCV13 and PPSV23", "description": "Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23\n\nPCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously"}, {"id": "OG001", "title": "PPSV23", "description": "Participants received PPSV23 alone\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "228.0", "lowerLimit": "174.2", "upperLimit": "362.3"}, {"groupId": "OG001", "value": "206.8", "lowerLimit": "130.1", "upperLimit": "323.8"}]}]}, {"title": "week 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "506.3", "lowerLimit": "349.6", "upperLimit": "670.9"}, {"groupId": "OG001", "value": "206.8", "lowerLimit": "130.1", "upperLimit": "323.8"}]}]}, {"title": "week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "502.9", "lowerLimit": "369.9", "upperLimit": "790.5"}, {"groupId": "OG001", "value": "449.4", "lowerLimit": "338.7", "upperLimit": "583.4"}]}]}, {"title": "week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "534.8", "lowerLimit": "325.4", "upperLimit": "688.4"}, {"groupId": "OG001", "value": "485.7", "lowerLimit": "321.2", "upperLimit": "588.6"}]}]}]}, {"type": "PRIMARY", "title": "Sum of Anti-pneumococcal IgG to Serotypes Common to PCV13 and PPSV23 at Baseline, Week 0, Week 8, Week 16", "description": "5 ml blood draw for assessment of IgG specific Antibody titers for serotypes common PCV13 \\& PPSV23. Measured as mcg/mL.", "populationDescription": "Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mcg/mL", "timeFrame": "Baseline, week 0, week 8, week 16", "groups": [{"id": "OG000", "title": "PCV13 and PPSV23", "description": "Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23\n\nPCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously"}, {"id": "OG001", "title": "PPSV23", "description": "Participants received PPSV23 alone\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "142.4", "lowerLimit": "110.7", "upperLimit": "246.8"}, {"groupId": "OG001", "value": "107.4", "lowerLimit": "92.9", "upperLimit": "161.8"}]}]}, {"title": "week 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "418.9", "lowerLimit": "303.2", "upperLimit": "525.1"}, {"groupId": "OG001", "value": "107.4", "lowerLimit": "92.9", "upperLimit": "161.8"}]}]}, {"title": "week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "362.8", "lowerLimit": "258.9", "upperLimit": "498.6"}, {"groupId": "OG001", "value": "229.4", "lowerLimit": "162.6", "upperLimit": "302.2"}]}]}, {"title": "week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "343.7", "lowerLimit": "221.5", "upperLimit": "447.1"}, {"groupId": "OG001", "value": "230.5", "lowerLimit": "149.5", "upperLimit": "302.1"}]}]}]}, {"type": "PRIMARY", "title": "Sum of Anti-pneumococcal IgG to Serotypes Unique to PPSV23 at Baseline, Week 0, Week 8 and Week 16.", "description": "5 ml blood draw for assessment of IgG specific Antibody titers for serotypes unique to PPSV23. Measured as mcg/mL.", "populationDescription": "Baseline = For arm PPSV23 baseline is 8 weeks prior to receiving PPSV-23. For arm PCV13 and PPSV23 baseline is day of receiving PCV-13. Week 0 = day of receiving PPSV-23 for both arms. Week 8 = eight weeks after receiving PPSV-23 for both arms. Week 16 = sixteen weeks after receiving PPSV-23 for both arms.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mcg/mL", "timeFrame": "Baseline, week 0, week 8, week 16", "groups": [{"id": "OG000", "title": "PCV13 and PPSV23", "description": "Participants received PPSV23 primed with PCV13. Participants received PCV13 8 weeks prior to receiving PPSV23\n\nPCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously"}, {"id": "OG001", "title": "PPSV23", "description": "Participants received PPSV23 alone\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "89.2", "lowerLimit": "64.1", "upperLimit": "120.9"}, {"groupId": "OG001", "value": "74.7", "lowerLimit": "41.0", "upperLimit": "160.2"}]}]}, {"title": "week 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.4", "lowerLimit": "56.2", "upperLimit": "152.4"}, {"groupId": "OG001", "value": "74.7", "lowerLimit": "41.0", "upperLimit": "160.2"}]}]}, {"title": "week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "174.2", "lowerLimit": "92.3", "upperLimit": "283.4"}, {"groupId": "OG001", "value": "220.0", "lowerLimit": "164.7", "upperLimit": "246.8"}]}]}, {"title": "week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "179.1", "lowerLimit": "96.9", "upperLimit": "277.0"}, {"groupId": "OG001", "value": "184.1", "lowerLimit": "171.0", "upperLimit": "255.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse Events were collected from baseline to end of study, approximately 16 weeks.", "eventGroups": [{"id": "EG000", "title": "PCV13 and PPSV23", "description": "Participants received PPSV23 primed with PCV13\n\nPCV13: Single 0.5 ml dose of PCV13 administered via intramuscular injection\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered 8 weeks after receiving PCV13 via intramuscularly or subcutaneously", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 0, "otherNumAtRisk": 8}, {"id": "EG001", "title": "PPSV23", "description": "Participants received PPSV23 alone\n\nPPSV23: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously", "deathsNumAffected": 0, "deathsNumAtRisk": 9, "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 0, "otherNumAtRisk": 9}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Avni Y. Joshi, M.D., M.S.", "organization": "Mayo Clinic", "email": "Joshi.Avni@mayo.edu", "phone": "507-284-3165"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-06-07", "uploadDate": "2021-09-23T14:41", "filename": "Prot_SAP_000.pdf", "size": 250001}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M13904", "name": "Pneumonia", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069443", "term": "Heptavalent Pneumococcal Conjugate Vaccine"}], "ancestors": [{"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M17360", "name": "Vaccines", "relevance": "LOW"}, {"id": "M412", "name": "Heptavalent Pneumococcal Conjugate Vaccine", "asFound": "Gonal-f", "relevance": "HIGH"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}